- Home
- PTPI
as 11-15-2024 4:00pm EST
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 3.0M | IPO Year: | N/A |
| Target Price: | $4.00 | AVG Volume (30 days): | 327.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $2.27 | Next Earning Date: | 11-13-2024 |
| Revenue: | $4,022,389 | Revenue Growth: | -42.41% |
| Revenue Growth (this year): | -4.8% | Revenue Growth (next year): | 0.76% |
Latest Petros Pharmaceuticals Inc. News
PTPI Breaking Stock News: Dive into PTPI Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
TipRanks
a month ago
Petros Pharmaceuticals Amends President’s Employment Terms
ACCESSWIRE
2 months ago
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
ACCESSWIRE
2 months ago
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Simply Wall St.
3 months ago
Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
ACCESSWIRE
4 months ago
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
ACCESSWIRE
4 months ago
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
CNW Group
5 months ago
Start Proud Opens the Market
Compare PTPI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTPI Petros Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.